New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2014
09:27 EDTXOMAXOMA data extremely encouraging, says Roth Capital
Roth Capital believes that data for XOMA's anti-IL-1b antibody gevokizumab in pyoderma gangrenosum was "extremely encouraging." The firm expects investors' appreciation for the company to increase as its antibody platform develops, and it keeps a Buy rating on the stock.
News For XOMA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
07:16 EDTXOMAAmerican Academy of Ophthalmology to hold annual meeting
AAO Annual Meeting 2014 is being held in Chicago on October 18-21.
October 16, 2014
07:23 EDTXOMAIBF Conferences to hold a summit
Ophthalmology Innovation Summit is being held in Chicago on October 16.
October 10, 2014
13:01 EDTXOMAXOMA management to meet with Maxim
Subscribe for More Information
October 9, 2014
09:08 EDTXOMAXOMA initiates dosing in XOMA 358 Phase 1 study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use